Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in iron chelation therapy.

H Cario1, G Janka-Schaub, G Janssen

  • 1Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Ulm, Eythstrasse 24, 89075 Ulm. holger.cario@uniklinik-ulm.de

Klinische Padiatrie
|May 26, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Implementation of biosecurity measures by hoof trimmers in Switzerland].

Schweizer Archiv fur Tierheilkunde·2023
Same author

[Prevalence of claw disorders in swiss cattle farms].

Schweizer Archiv fur Tierheilkunde·2021
Same author

[Evaluation of a novel training course for hoof trimmers to participate in a Swiss national cattle claw health monitoring programme].

Schweizer Archiv fur Tierheilkunde·2021
Same author

Rapamycin-based graft-versus-host disease prophylaxis increases the immunosuppressivity of myeloid-derived suppressor cells without affecting T cells and anti-tumor cytotoxicity.

Clinical and experimental immunology·2020
Same author

The Refeeding Syndrome revisited: you can only diagnose what you know.

European journal of clinical nutrition·2019
Same author

Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study.

Journal of neuro-oncology·2019
Same journal

Guidance for the Diagnosis and Treatment of Rare Embryonal and Sarcomatous Brain Tumors-a Report from the Central Nervous System-International Registry for Rare Embryonal and Sarcomatous Tumors German Society of Pediatric Oncology and Hematology Study Group.

Klinische Padiatrie·2026
Same journal

Klinische Padiatrie·2026
Same journal

Association of Fat-free Mass Index and Body Mass Index on Pulmonary Function Tests in Children with Rheumatological Disease-associated Interstitial Lung Disease.

Klinische Padiatrie·2026
Same journal

Synchronous Differentiated Thyroid Carcinoma and Nonthyroid Malignancies in Pediatric Patients: A Registry-based Case Series.

Klinische Padiatrie·2026
Same journal

Intrauterine Ulceration of the Lower Limbs: A Not-so-rare Complication Following Vesicoamniotic Shunting with Somatex.

Klinische Padiatrie·2026
Same journal

Letter to the Editor Regarding the Article "Near-Fatal Asthma Due to Severe Airway Mucus Plugging in a 12-Year-Old Boy".

Klinische Padiatrie·2026
See all related articles

Iron overload can now be treated with three chelating agents: desferrioxamine (DFO), deferiprone (DFP), and deferasirox (DSX). New methods like cardiac MRI assess treatment effectiveness, improving patient outcomes.

Area of Science:

  • Hematology
  • Pharmacology
  • Medical Imaging

Background:

  • Secondary hemosiderosis treatment has evolved since 1962, initially relying on desferrioxamine (DFO) via subcutaneous infusion.
  • The development of oral iron chelators, like deferiprone (DFP), faced challenges but is now used for thalassemia major.
  • Recent advancements include new iron overload assessment methods and novel chelating agents, improving patient care.

Purpose of the Study:

  • To review the progress in iron chelation therapy for secondary hemosiderosis.
  • To highlight the efficacy of different chelating agents, including oral options.
  • To discuss the impact of new assessment methods on treatment strategies.

Main Methods:

  • Review of clinical research and drug development in iron chelation.

Related Experiment Videos

  • Utilizing cardiac T2 (*) MRI to assess myocardial siderosis.
  • Analysis of clinical trials comparing DFO, DFP, and deferasirox (DSX).

    • Main Results:

    • Cardiac T2 (*) MRI studies suggest deferiprone (DFP) is superior to desferrioxamine (DFO) for myocardial siderosis.
    • Combination therapy with DFO and DFP shows additive/synergistic effects for iron elimination.
    • Deferasirox (DSX) demonstrates good efficacy and tolerability in transfusional hemosiderosis.

    Conclusions:

    • Patients now have a choice of three chelating agents: DFO, DFP, and DSX.
    • Tailored treatment strategies can lead to improved life expectancy and quality of life.
    • Ongoing research, particularly long-term studies on DSX, will further define optimal iron overload management.